216 related articles for article (PubMed ID: 17574083)
1. Cardiovascular safety of rosiglitazone.
Krall RL
Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
[No Abstract] [Full Text] [Related]
2. [Doubts as to the cardiovascular safety of rosiglitazone].
Wolffenbuttel BH
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577
[No Abstract] [Full Text] [Related]
3. [Doubts as to the cardiovascular safety of rosiglitazone].
Hoekstra JB; Bossuyt PM; de Vries JH
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
[TBL] [Abstract][Full Text] [Related]
4. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
5. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
6. Rosiglitazone: seeking a balanced perspective.
The Lancet
Lancet; 2007 Jun; 369(9576):1834. PubMed ID: 17544746
[No Abstract] [Full Text] [Related]
7. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
8. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
9. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
10. Is rosiglitazone as safe as BARI 2D and the reanalysis of RECORD imply?
DiNicolantonio JJ; Meier P
Cardiology; 2014; 127(3):152-4. PubMed ID: 24335113
[No Abstract] [Full Text] [Related]
11. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
12. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Boyle P
South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
[No Abstract] [Full Text] [Related]
13. Editorial: What have we lost in the wake of the rosiglitazone controversy?
Zarich SW; Nesto RW
Endocr Pract; 2009 Apr; 15(3):273-4. PubMed ID: 19364699
[No Abstract] [Full Text] [Related]
14. In brief: rosiglitazone (Avandia) unbound.
Med Lett Drugs Ther; 2014 Feb; 56(1435):12. PubMed ID: 24662977
[No Abstract] [Full Text] [Related]
15. Rosiglitazone and cardiovascular risk: weighing recent evidence.
Stafylas PC; Sarafidis PA; Lasaridis AN
J Cardiometab Syndr; 2007; 2(4):295-6. PubMed ID: 18059214
[No Abstract] [Full Text] [Related]
16. Thiazolidinediones, deadly sins, surrogates, and elephants.
Cleland JG; Atkin SL
Lancet; 2007 Sep; 370(9593):1103-4. PubMed ID: 17905146
[No Abstract] [Full Text] [Related]
17. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant PJ
Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
[No Abstract] [Full Text] [Related]
18. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Marx N
Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
[No Abstract] [Full Text] [Related]
19. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
Odom J; Williamson B; Carter L
Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
[No Abstract] [Full Text] [Related]
20. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
